文献速递临床试验与 GCP流行病学与生物统计

公共卫生紧急事件期间中药临床试验注册质量调查

Calling for improved quality in the registration of traditional Chinese medicine during the public health emergency: a survey of trial registries for COVID-19, H1N1, and SARS.
PubMed 文献 · Trials · 2021-03-05

该研究于2020年4月30日检索WHO ICTRP和ChiCTR,评估COVID-19、H1N1和SARS中药临床试验注册质量,共纳入136条记录(COVID-19 129条、H1N1 7条)。结果显示注册质量较低,干预措施详细信息报告率46.6%,主要结局报告率37.7%,关键次要结局报告率18.4%,无摘要结果报告;中药特异性条目报告率极低。

要点

  • 中药临床试验注册中干预措施和结局报告不完整,主要结局报告率仅37.7%。
  • 中药特异性信息严重缺失,无注册报告中药背景和理论依据。
  • 需改进中药临床试验注册的详细报告和质量。

核心结论

  • 尽管中药临床试验注册数量增加,但注册质量较低。
  • 应通过更详细报告干预措施、结局、中药特异性信息及共享结果数据来提高注册质量。

研究设计与样本

  • 于2020年4月30日检索WHO ICTRP和ChiCTR,纳入136条中药临床试验注册记录(COVID-19 129条、H1N1 7条)。
  • 基于WHO试验注册数据集(版本1.3.1)及中药信息额外条目评估注册质量。

主要发现

  • 干预措施详细信息报告率为46.6%,主要结局报告率为37.7%,关键次要结局报告率为18.4%。
  • 无注册记录报告摘要结果(0%)。
  • 无注册记录报告中药背景和理论依据(0%),仅6.6%提供中药诊断标准或干预描述,27.9%提供中药结局。

关键数值与推荐

  • 干预措施详细信息报告率46.6%。
  • 主要结局报告率37.7%,关键次要结局报告率18.4%。
  • 摘要结果报告率0%。
  • 中药背景和理论依据报告率0%,中药诊断标准或干预描述报告率6.6%,中药结局报告率27.9%。

临床怎么用

  • 提示临床研究者应完善中药临床试验注册中干预措施和结局的详细报告。
  • 应重视中药特异性信息的注册报告,并共享结果数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the registration quality of traditional Chinese medicine (TCM) clinical trials for COVID-19, H1N1, and SARS. METHOD: We searched for clinical trial registrations of TCM in the WHO International Clinical Trials Registry Platform (ICTRP) and Chinese Clinical Trial Registry (ChiCTR) on April 30, 2020. The registration quality assessment is based on the WHO Trial Registration Data Set (Version 1.3.1) and extra items for TCM information, including TCM background, theoretical origin, specific diagnosis criteria, description of intervention, and outcomes. RESULTS: A total of 136 records were examined, including 129 severe acute respiratory syndrome coronavirus 2 (COVID-19) and 7 H1N1 influenza (H1N1) patients. The deficiencies in the registration of TCM clinical trials (CTs) mainly focus on a low percentage reporting detailed information about interventions (46.6%), primary outcome(s) (37.7%), and key secondary outcome(s) (18.4%) and a lack of summary result (0%). For the TCM items, none of the clinical trial registrations reported the TCM background and rationale; only 6.6% provided the TCM diagnosis criteria or a description of the TCM intervention; and 27.9% provided TCM outcome(s). CONCLUSION: Overall, although the number of registrations of TCM CTs increased, the registration quality was low. The registration quality of TCM CTs should be improved by more detailed reporting of interventions and outcomes, TCM-specific information, and sharing of the result data.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kuang Z, Li X, Cai J, et al. Calling for improved quality in the registration of traditional Chinese medicine during the public health emergency: a survey of trial registries for COVID-19, H1N1, and SARS. Trials. 2021. PMID: 33673845. doi:10.1186/s13063-021-05113-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。